Series B - Grey Wolf Therapeutics
Investment Firm
Overview
First-of-its-kind antigen modulation to address immune dysfunction in oncology and autoimmunity
Announced Date
May 23, 2024
Closed on Date
May 23, 2024
Funding Type
Series B
Highlights
N/A
Location
N/A
Social
N/A
Participant Investors
7
Round Details and Background
Grey Wolf Therapeutics raised $50000000 on 2024-05-23 in Series B
First-of-its-kind antigen modulation to address immune dysfunction in oncology and autoimmunity
Company Funding History
5
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Apr 01, 2018 | - | 7.0M | ||
| Jan 09, 2020 | 2 | - | 3.3M | |
| Jan 26, 2023 | 6 | - | 49.2M | |
| May 23, 2024 | 7 | - | 50.0M |
Recent Activity
There is no recent news or activity for this profile.